Picture Demy-Colton BioFuture 2024 NYC 3 Biotech Breakthroughs 650x100px
Document › Details

Tempus Labs, Inc.. (2/23/23). "Press Release: Tempus Announces New Multi-omics Collaboration with Actuate Therapeutics".

Organisations Organisation Tempus Labs Inc.
  Organisation 2 Actuate Therapeutics Inc.
Products Product personalised medicine / precision medicine
  Product 2 elraglusib
Index term Index term Actuate Therapeutics–Tempus Labs: AI-based drug development, 202302– collab multi-omics support for phase 1/2 study of elraglusib
Persons Person Yasiejko, Michael (Tempus Labs 202302 EVP)
  Person 2 Mazar, Andrew P. (Actuate Therapeutics 202302 COO)

Tempus, a leader in artificial intelligence and precision medicine, today announced a brand-new multi-omics collaboration with Actuate Therapeutics, Inc. (Actuate), a clinical-stage biopharmaceutical company, to support its ongoing Phase 1/2 Study of elraglusib, formerly known as 9-ING-41 (NCT03678883). The Tempus’ xF+ liquid biopsy and Research Use Only (RUO) DNA methylation tests will be used to help discover and further validate biomarker profiles in patients who may benefit from treatment with elraglusib, a selective GSK-3ß inhibitor.

Tempus is implementing a multi-omics approach to this project in which the datasets of different omic groups are combined in an effort to improve research and increase novel scientific insights. This approach will help make new discoveries possible including ones that may have been missed using a single method alone.

GSK-3ß is an enzyme that drives tumor progression by promoting cancer cell proliferation, resistance, and survival in progressive and metastatic disease. Currently, several prognostic biomarker profiles that may derive benefit from elraglusib are being evaluated. The data created from the results of both Tempus’ xF+ and RUO DNA methylation tests will help identify patient populations that may respond to this specific therapeutic.

“We are looking forward to supporting Actuate’s study by using both our multi-omic and multimodal data to assist in the discovery and validation of novel drug targets and biomarkers,” said Michael Yasiejko, Executive Vice President at Tempus. “Tempus’ comprehensive platform provides extensive, multi-omics offerings throughout the clinical development cycle including the development of multimodal datasets for more holistic understanding of patient populations.”

“Elraglusib is currently advancing into multiple phase 2 clinical trials including a randomized study in patients with metastatic pancreatic cancer ” said Andrew Mazar, Ph.D., Chief Operating Officer at Actuate Therapeutics. “We have observed evidence of elraglusib clinical benefit in multiple advanced cancer histologies that may correlate with biomarker profiles that will be identified or further explored using Tempus’ xF+ and RUO DNA methylation platforms in patient cfDNA. The ability to apply the Tempus liquid biopsy molecular testing approaches may provide a novel, patient-friendly analytics platform that will advance how precision approaches can be incorporated in clinical development.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. For additional information, please visit the Company’s website at

Record changed: 2024-01-20


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Tempus Labs Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top